Navigation Links
Oncolytics Biotech Inc. Completes Dose Escalation in Combination REOLYSIN(R)/Docetaxel Trial
Date:8/11/2008

CALGARY, Aug. 11 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) has completed patient enrolment in the dose escalation portion of its U.K. clinical trial to evaluate the anti-tumour effects of systemic administration of REOLYSIN(R) in combination with docetaxel (Taxotere(R)) in patients with advanced cancers including bladder, prostate, lung and upper gastro-intestinal. The principal investigator is Professor Hardev Pandha of the Royal Surrey Hospital, U.K.

The trial (REO 010) has two components. The first is an open-label, dose-escalating, non-randomized study of REOLYSIN(R) given intravenously with docetaxel every three weeks. Standard dosages of docetaxel were delivered to patients with escalating dosages of REOLYSIN(R) intravenously. The second component of the trial includes the enrolment of a further nine patients at the top dose of REOLYSIN(R) in combination with a standard dosage of docetaxel.

"We have completed the dose escalation stage of the study," said Prof. Pandha. "Patients enrolled had previously undergone significant treatment with combination chemotherapy. The combination of REOLYSIN(R) and taxotere was safe, well tolerated with no obvious toxicity related specifically to REOLYSIN(R). Efficacy of the combination was encouraging: both objective anti-tumour responses and disease stabilization were observed radiologically."

Eligible patients include those who have been diagnosed with advanced or metastatic solid tumours including bladder, lung, prostate or upper gastro-intestinal cancers that are refractory (have not responded) to standard therapy or for which no curative standard therapy exists. The primary objective of the trial is to determine the Maximum Tolerated Dose (MTD), Dose-Limiting Toxicity (DLT), recommended dose and dosing schedule and safety profile of REOLYSIN(R) when administered in combination with docetaxel. Secondary objectives include the evaluation of immune resp
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2009)... InSound is honored by latest award fo... Newark, CA (PRWEB) November 16, 2009 -- Popu...visible” hearing aid from InSound Medical a ...rd in the Health category.    ...ed to reside deep in the hearing canal for up to f...
(Date:11/18/2009)...y personnel need to be able to find explosive mate...em. To aid such searches, the National Institute o...om the Department of Homeland Security, has develo...eference Material (SRM) 2905, Trace Particulate Ex...ay methods, the SRM will be helpful in calibrating...
(Date:11/18/2009)... Vernier,s experience in data analysis combined wi...am kits and curricula provide state-of-the...BEAVERTON, Ore., Nov. 18 Vernier S...l science interfaces, sensors, and software and Bi...urer and distributor of life science research and ...
(Date:11/18/2009)...SISSAUGA, ON, Nov. 18 /PRNewswire-FirstCall/ - YM ...fe sciences product development company that ident...g cancer-related products at various stages of dev...uating nimotuzumab were presented today in a poste... Cancer Therapeutics conference in Boston, Massach...
Breaking Biology Technology:Popular Science Awards Lyric “Invisible” Hearing Aid 2009 “Best of What's New” Award 2Popular Science Awards Lyric “Invisible” Hearing Aid 2009 “Best of What's New” Award 3New NIST trace explosives standard slated for homeland security duty 2Vernier and Bio-Rad to Offer Enhanced Solutions for Biotechnology Education 2YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB RESULTS IN ADVANCED TRIPLE-NEGATIVE BREAST CANCER MODEL PRESENTED AT AACR-NCI-EORTC MEETING 2YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB RESULTS IN ADVANCED TRIPLE-NEGATIVE BREAST CANCER MODEL PRESENTED AT AACR-NCI-EORTC MEETING 3
...enosumab is a new drug being,studied to prevent fr...al,therapy. Results of a phase 3 clinical trial us... San Antonio Breast Cancer Symposium by Georgiana,... Denosumab is a highly specific antibody that int...zed cells that break down bone. Because it is,high...
...ontinuing Interest in Peregrine,s Anti-PS Technolo... -, TUSTIN, Calif., Dec. 14 Peregrine,Pharmaceut...pharmaceutical,company developing monoclonal antib...virus (HCV) infection, today announced the sudden ...ract award with the Defense Threat,Reduction Agenc...
...l Potential Uses, Excluding U.S. and Japan, No Ot...ase BASINGSTOKE, England and PHILADELPHIA, Decemb...Q),the global specialty biopharmaceutical company,...e rights, excluding the U.S. and Japan, to AT-1001...1 is Alba,s lead inhibitor,of barrier dysfunction ...
Other Biology Technology:New Drug to Prevent Bone Loss Caused by Breast Cancer Treatment 2Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program 2Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program 3Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program 4Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation 2Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation 3
(Date:11/19/2009)...tries of the world. It is widely used for human co...It also is considered an exemplar plant species fo... genome architecture. The authors of the research ...t description of the B73 maize genome to probe som... plant biology. The ten papers consider maize cent...
(Date:11/19/2009)... multi-institutional effort co-led by three Cold S...ed today in publication of a landmark series of pa...dented detail the DNA sequence of maize ( Zea mays...rth American consumers, is one of the world,s most...al crop grown in the United States, representing $...
(Date:11/19/2009)...swire-FirstCall/ -- BIO-key International, Inc. (O...lic safety and finger-based biometric identificati...er Meeting held today was adjourned without any ac... ,, (Logo: http://www.newscom.com/cgi-bin/prnh....3% of the 35 million votes cast voted in favor of...
Breaking Biology News(10 mins):PLoS Genetics 2009 maize genome collection 2PLoS Genetics 2009 maize genome collection 3PLoS Genetics 2009 maize genome collection 4Reference genome of maize, most important US crop, is published by team co-led by CSHL scientists 2Reference genome of maize, most important US crop, is published by team co-led by CSHL scientists 3Reference genome of maize, most important US crop, is published by team co-led by CSHL scientists 4BIO-key(R) Provides Update to Special Shareholder Meeting 2BIO-key(R) Provides Update to Special Shareholder Meeting 3Finally The Round Diet 21 A Diet Simple Enough that Even a Kindergartener Can Follow It 50523 1Finally The Round Diet 21 A Diet Simple Enough that Even a Kindergartener Can Follow It 50523 2WellPoint Recovers and Saves 2475 Million Through Anti Fraud Programs and Investigations in 2008 50521 1WellPoint Recovers and Saves 2475 Million Through Anti Fraud Programs and Investigations in 2008 50521 2WellPoint Recovers and Saves 2475 Million Through Anti Fraud Programs and Investigations in 2008 50521 3Hospital Improves Patient Experience by Adding Email and Web Access in Patient Rooms With Virtual Linux Desktops 50519 1Hospital Improves Patient Experience by Adding Email and Web Access in Patient Rooms With Virtual Linux Desktops 50519 2Hospital Improves Patient Experience by Adding Email and Web Access in Patient Rooms With Virtual Linux Desktops 50519 3Hospital Improves Patient Experience by Adding Email and Web Access in Patient Rooms With Virtual Linux Desktops 50519 4Hospital Improves Patient Experience by Adding Email and Web Access in Patient Rooms With Virtual Linux Desktops 50519 5
...t suffering from depression. Children take on an e...t and for other family members. It is therefore im...s and have support functions in place for the whol...This is the conclusion of a thesis from the Sahlgr... Registered Nurse Britt Hedman Ahlstrm has examin...
...daq: AWRE ), a leading supplier of broadband tec...hat its Board of Directors has approved a modified...00 shares, or approximately 15%, of its outstandin... share purchase rights), at a price in the range o...e purchase price of approximately $9.1 million. T...
...man, co-author of the study titled "Drought Sensit... of the TEAM Network at Conservation International...ing on energy security and food security, this stu...tem security in short, how nature keeps us health... problem; drying climate is just as bad or worse f...
Other Biology News:Children seriously affected when a parent suffers from depression 2Aware, Inc. Commences Dutch Auction Tender Offer 2Aware, Inc. Commences Dutch Auction Tender Offer 3Aware, Inc. Commences Dutch Auction Tender Offer 4
Bovine IgG2 ELISA Kit from Bethyl Laboratories
Dog IgE ELISA Kit from Bethyl Laboratories
PCP ELISA Kit, Single from Bio-Quant Inc.
...opment ,Antibody Titer and Optimal Conditions Anal... and Tissues ,Double Antibody Labeling of Cells an...ogold, and Fluorescent detection ,Light, Fluoresce...n Transgenic Animals ,Hundreds of Specialty Marker...
Biology Products: